A detailed history of Wells Fargo & Company transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Wells Fargo & Company holds 6,410 shares of ATAI stock, worth $10,832. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,410
Previous 6,410 -0.0%
Holding current value
$10,832
Previous $8,000 12.5%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$1.5 - $2.19 $9,615 - $14,037
6,410 New
6,410 $12,000
Q2 2022

Aug 12, 2022

BUY
$3.03 - $5.32 $12,120 - $21,280
4,000 New
4,000 $15,000
Q1 2022

May 16, 2022

SELL
$4.66 - $7.66 $37 - $61
-8 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$6.82 - $17.8 $54 - $142
8 New
8 $0

Others Institutions Holding ATAI

About ATAI Life Sciences N.V.


  • Ticker ATAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 165,875,008
  • Market Cap $280M
  • Description
  • Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...
More about ATAI
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.